BioDrugs

, Volume 22, Issue 3, pp 177–188 | Cite as

Mecasermin

Adis Drug Profile

Abstract

▴ Mecasermin (recombinant human insulin-like growth factor-I [IGF-I]) is approved in the US for the long-term treatment of growth failure in children with severe primary IGF-I deficiency or with growth hormone (GH) gene deletion who have developed neutralizing antibodies to GH, and in the EU for the long-term treatment of growth failure in children and adolescents with severe primary IGF-I deficiency.

▴ Subcutaneous mecasermin 0.12 mg/kg twice daily stimulated linear growth in children with growth failure and severe IGF-I deficiency associated with GH insensitivity, according to the results of a noncomparative, multicenter trial (n = 76) [mean duration of therapy 4.4 years; range 0.04–12.5 years]. During the first year of treatment, height velocity significantly increased from a mean 2.8 cm/year at baseline to a mean 8.0 cm/year; mean growth velocities remained above baseline for up to 8 years.

▴ Mecasermin also promoted statural growth in a small noncomparative trial in children with growth failure and GH insensitivity syndrome (n = 8). After 6.5–7.5 years of mecasermin therapy, the mean increase in the height standard deviation score was +1.4.

▴ Mecasermin was also shown to have beneficial effects in various other conditions including diabetes mellitus and anorexia nervosa.

▴ Subcutaneous mecasermin was generally well tolerated in children with severe IGF-I deficiency associated with GH insensitivity.

References

  1. 1.
    Backeljauw PF, Chemausek SD. Treatment of insulin-like growth factor deficiency with IGF-I: studies in humans. Horm Res 2006; 65Suppl. 1: 21–7PubMedCrossRefGoogle Scholar
  2. 2.
    Clark RG. Recombinant human insulin-like growth factor I (IGF-I): risks and benefits of normalizing blood IGF-I concentrations. Horm Res 2004; 62Suppl. 1: 93–100PubMedCrossRefGoogle Scholar
  3. 3.
    Mauras N, Beaufrere B. Recombinant human insulin-like growth factor-I enhances whole body protein anabolism and significantly diminishes the protein catabolic effects of prednisome in humans without a diabetogenic effect. J Clin Endocrinol Metab 1995; 80(3): 869–74PubMedCrossRefGoogle Scholar
  4. 4.
    Mauras N, Martinez V, Rini A, et al. Recombinant human insulin-like growth factor I has significant anabolic effects in adults with growth hormone receptor deficiency: studies on protein, glucose, and lipid metabolism. J Clin Endocrinol Metab 2000 Sep; 85(9): 3036–42PubMedCrossRefGoogle Scholar
  5. 5.
    Kaplan SA, Cohen P. Review: the somatomedin hypothesis 2007: 50 years later. J Clin Endocrinol Metab 2007 Dec; 92(12): 4529–35PubMedCrossRefGoogle Scholar
  6. 6.
    Tercica, Inc. Increlex™ (mecasermin [rDNA origin] injection): US prescribing information [online]. Available from URL: http://www.tercica.com [Accessed 2008 Mar 4]
  7. 7.
    European Medicines Agency. Mecasermin: scientific discussion [online]. Available from URL: http://www.emea.europa.eu [Accessed 2008 Mar 3]
  8. 8.
    Rosenfeld RG. IGF-I therapy in growth disorders. Eur J Endocrinol 2007 Aug; 157Suppl. 1: S57–60PubMedCrossRefGoogle Scholar
  9. 9.
    Rosenbloom AL. Is there a role for recombinant insulin-like growth factor-I in the treatment of idiopathic short stature? Lancet 2006 Aug 12; 368(9535): 612–6PubMedCrossRefGoogle Scholar
  10. 10.
    Dunger D, Yuen K, Ong K. Insulin-like growth factor I and impaired glucose tolerance. Horm Res 2004; 62Suppl. 1: 101–7PubMedCrossRefGoogle Scholar
  11. 11.
    Mauras N, Martha PM, Quarmby V, et al. rhIGF-I administration in humans: differential metabolic effects of bolus vs. continuous subcutaneous delivery. Am J Physiol Endocrinol Metab 1997 Apr; 35: E628–33Google Scholar
  12. 12.
    European Medicines Agency. Mecasermin: summary of product characteristics [online]. Available from URL: http://www.emea.europa.eu [Accessed 2008 Mar 3]
  13. 13.
    Schoenle E, Zapf J, Humbel RE. Insulin-like growth factor I stimulates growth in hypophysectomized rats. Nature 1982 Mar 18; 296(5854): 252–3PubMedCrossRefGoogle Scholar
  14. 14.
    Tomas FM, Knowles SE, Chandler CS, et al. Anabolic effects of insulin-like growth factor-I (IGF-I) and an IGF-I variant in normal female rats. J Endocrinol 1993 Jun; 137(3): 413–21PubMedCrossRefGoogle Scholar
  15. 15.
    Douglas RG, Gluckman PD, Ball K, et al. The effects of infusion of insulinlike growth factor (IGF) I, IGF-II, and insulin on glucose and protein metabolism in fasted lambs. J Clin Invest 1991 Aug; 88(2): 614–22PubMedCrossRefGoogle Scholar
  16. 16.
    Jacob R, Barrett E, Plewe G, et al. Acute effects of insulin-like growth factor I on glucose and amino acid metabolism in the awake fasted rat. J Clin Invest 1989 May; 83(5): 1717–23PubMedCrossRefGoogle Scholar
  17. 17.
    Zapf J, Hauri C, Waldvogel M, et al. Acute metabolic effects and half-lives of intravenously administered insulinlike growth factors I and II in normal and hypophysectomized rats. J Clin Invest 1986 Jun; 77(6): 1768–75PubMedCrossRefGoogle Scholar
  18. 18.
    Chernausek SD, Backeljauw PF, Frane J, et al. Long-term treatment with recombinant insulin-like growth factor (IGF)-I in children with severe IGF-I deficiency due to growth hormone insensitivity. J Clin Endocrinol Metab 2007 Mar; 92(3): 902–10PubMedCrossRefGoogle Scholar
  19. 19.
    Backeljauw PF, Underwood LE. Therapy for 6.5–7.5 years with recombinant insulin-like growth factor I in children with growth hormone insensitivity syndrome: a clinical research center study. J Clin Endocrinol Metab 2001 Apr; 86(4): 1504–10PubMedCrossRefGoogle Scholar
  20. 20.
    Guevara-Aguirre J, Guevara-Aguirre M, Rosenbloom AL. Absence of hypoglycemia in response to varying doses of recombinant human insulin-like growth factor-I (rhIGF-I) in children and adolescents with low serum concentrations of IGF-I. Acta Paediatr 2006 Feb; 95(2): 199–202PubMedCrossRefGoogle Scholar
  21. 21.
    Mauras N, Horber FF, Haymond MW. Low dose recombinant human insulin-like growth factor-I fails to affect protein anabolism but inhibits islet cell secretion in humans. J Clin Endocrinol Metab 1992 Nov; 75(5): 1192–7PubMedCrossRefGoogle Scholar
  22. 22.
    Laager R, Ninnis R, Keller U. Comparison of the effects of recombinant human insulin-like growth factor-I and insulin on glucose and leucine kinetics in humans. J Clin Invest 1993 Oct; 92(4): 1903–9PubMedCrossRefGoogle Scholar
  23. 23.
    Turkalj I, Keller U, Ninnis R, et al. Effect of increasing doses of recombinant human insulin-like growth factor-I on glucose, lipid, and leucine metabolism in man. J Clin Endocrinol Metab 1992 Nov; 75(5): 1186–91PubMedCrossRefGoogle Scholar
  24. 24.
    Guler HP, Zapf J, Froesch ER. Short-term metabolic effects of recombinant human insulin-like growth factor I in healthy adults. N Engl J Med 1987 Jul 16; 317(3): 137–40PubMedCrossRefGoogle Scholar
  25. 25.
    Mauras N. Combined recombinant human growth hormone and recombinant human insulin-like growth factor I: lack of synergy on whole body protein anabolism in normally fed subjects. J Clin Endocrinol Metab 1995 Sep; 80(9): 2633–7PubMedCrossRefGoogle Scholar
  26. 26.
    Fervenza FC, Friedlaender MM, Ike JO, et al. Insulin-like growth factor-I treatment to enhance renal function in advanced chronic renal failure. Ren Fail 1998; 20(2): 349–56PubMedCrossRefGoogle Scholar
  27. 27.
    FDA. Center for Drug Evaluation and Research approval package for: application number NDA 21–839: medical review(s) [online]. Available from URL: http://www.fda.gov/cder/foi/nda/2005/021839_S000_Increlex_MedR.pdf [Accessed 2008 Mar 3]
  28. 28.
    Backeljauw PF, Underwood LE, and the GHIS Collaborative Group. Prolonged treatment with recombinant insulin-like growth factor-I in children with growth hormone insensitivity syndrome: a clinical research center study. J Clin Endocrinol Metab 1996 Sep; 81(9): 3312–7PubMedCrossRefGoogle Scholar
  29. 29.
    Underwood LE, Backeljauw P, Duncan V. Effects of insulin-like growth factor I treatment on statural growth, body composition and phenotype of children with growth hormone insensitivity syndrome. Acta Paediatr Suppl. 1999 Feb; 88(428): 182–4PubMedCrossRefGoogle Scholar
  30. 30.
    Riedl S, Frisch H. Effects of growth hormone (GH) and insulin-like growth factor-I therapy in patients with gene defects in the GH axis. J Pediatr Endocrinol Metab 2006 Mar; 19(3): 229–36PubMedCrossRefGoogle Scholar
  31. 31.
    Walker JL, Van Wyk JJ, Underwood LE. Stimulation of statural growth by recombinant insulin-like growth factor I in a child with growth hormone insensitivity syndrome (Laron type). J Pediatr 1992 Oct; 121(4): 641–6PubMedCrossRefGoogle Scholar
  32. 32.
    Walker JL, Ginalska-Malinowska M, Romer TE, et al. Effects of the infusion of insulin-like growth factor I in a child with growth hormone insensitivity syndrome (Laron dwarfism). N Engl J Med 1991 May 23; 324(21): 1483–8PubMedCrossRefGoogle Scholar
  33. 33.
    Thrailkill KM, Quattrin T, Baker L, et al. Cotherapy with recombinant human insulin-like growth factor I and insulin improves glycemic control in type 1 diabetes. Diabetes Care 1999 Apr; 22(4): 585–92PubMedCrossRefGoogle Scholar
  34. 34.
    Thrailkill K, Quattrin T, Baker L, et al. Dual hormonal replacement therapy with insulin and recombinant human insulin-like growth factor (IGF)-I in insulin-dependent diabetes mellitus: effects on the growth hormone/IGF/IGF-binding protein system. J Clin Endocrinol Metab 1997 Apr; 82(4): 1181–7PubMedCrossRefGoogle Scholar
  35. 35.
    Quattrin T, Thrailkill K, Baker L, et al. Dual hormonal replacement with insulin and recombinant human insulin-like growth factor I in IDDM: effects on glycemic control, IGF-I levels, and safety profile. Diabetes Care 1997 Mar; 20(3): 374–80PubMedCrossRefGoogle Scholar
  36. 36.
    Moses AC, Young SCJ, Morrow LA, et al. Recombinant human insulin-like growth factor I increases insulin sensitivity and improves glycemic control in type II diabetes. Diabetes 1996 Jan; 45: 91–100PubMedCrossRefGoogle Scholar
  37. 37.
    Waters D, Danska J, Hardy K, et al. Recombinant human growth hormone, insulin-like growth factor 1, and combination therapy in AIDS-associated wasting: a randomized, double-blind, placebo-controlled trial. Ann Intern Med 1996 Dec 1; 125(11): 865–72PubMedGoogle Scholar
  38. 38.
    Lee PDK, Pivarnik JM, Bukar JG, et al. A randomized, placebo-controlled trial of combined insulin-like growth factor I and low dose growth hormone therapy for wasting associated with human immunodeficiency virus infection. J Clin EndocrinolMetab 1996 Aug; 81(8): 2968–75CrossRefGoogle Scholar
  39. 39.
    Nguyen B-Y, Clerici M, Venzon DJ, et al. Pilot study of the immunologic effects of recombinant human growth hormone and recombinant insulin-like growth factor in HIV-infected patients. AIDS 1998 May 28; 12(8): 895–904PubMedCrossRefGoogle Scholar
  40. 40.
    Grinspoon S, Thomas L, Miller K, et al. Effects of recombinant human IGF-I and oral contraceptive administration on bone density in anorexia nervosa. J Clin Endocrinol Metab 2002 Jun; 87(6): 2883–91PubMedCrossRefGoogle Scholar
  41. 41.
    American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th ed., text revision. Washington, DC: American Psychiatric Association, 2000Google Scholar
  42. 42.
    Thompson JL, Butterfield GE, Gylfadottir UK, et al. Effects of human growth hormone, insulin-like growth factor I, and diet and exercise on body composition of obese postmenopausal women. J Clin Endocrinol Metab 1998 May; 83(5): 1477–84PubMedCrossRefGoogle Scholar
  43. 43.
    Bucuvalas JC, Chernausek SD, Alfaro MP, et al. Effect of insulinlike growth factor-1 treatment in children with cystic fibrosis. J Pediatr Gastroenterol Nutr 2001 Nov; 33(5): 576–81PubMedCrossRefGoogle Scholar
  44. 44.
    Kudsk KA, Mowatt-Larssen C, Bukar J, et al. Effect of recombinant human insulin-like growth factor I and early total parenteral nutrition on immune depression following severe head injury. Arch Surg 1994 Jan; 129: 66–71PubMedCrossRefGoogle Scholar

Copyright information

© Adis Data Information BV 2008

Authors and Affiliations

  1. 1.Wolters Kluwer Health ¦ AdisMairangi Bay, North Shore 0754, AucklandNew Zealand
  2. 2.Wolters Kluwer HealthConshohockenUSA

Personalised recommendations